U.S., March 28 -- ClinicalTrials.gov registry received information related to the study (NCT07496463) titled 'Setmelanotide to Treat Obesity in a Patient With Pseudohypoparathyroidism Type 1a (PHP1a)' on March 22.
Brief Summary: We plan to test the efficacy and safey of 6-months of open-label setmelanotide to treat obesity in a single patient with pseudohypoparathyroidism type 1a due to a GNAS mutation.
Study Start Date: April 01
Study Type: INTERVENTIONAL
Condition:
Pseudohypoparathyroidism Type 1a
Obesity
Intervention:
DRUG: Setmelanotide
Setmelanotide will be prescribed at the standard initial dose of 2 mg SC daily. The treatment will be uptitrated at the 2-Week visit to 3 mg SC daily if tolerated. We will continue this maximal d...